NEUROMYELITIS OPTICS THERAPY MARKET ANALYSIS

Regional Analysis

Global Neuromyelitis Optica Therapy Market Regional Analysis

Among regions, North America is expected to account for highest market share in the global neuromyelitis optica therapy market, owing to factors such as increasing approval of drugs for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company. For instance, in January 2019, Alexion Pharmaceuticals, Inc. received approval by the U.S Food and Drug Administartion (FDA) for eculizumab (Soliris) drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients.  Furthermore, from the same source, eculizumab (soliris) has reduced the need of corticosteroid and plasma exchange to prevent acute attack in patients, who are suffering from neuromyelitis optica spectrum disorder (NMOSD).

Asia Pacific is expected to exhibit highest CAGR in the global neuromyelitis optica therapy market in the forecast period due to increasing approval of drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company. For instance, in November 2019, Alexion Pharmaceuticals, Inc. received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its Soliris (eculizumab) drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) to prevent relapse in patient.  

Furthermore, increasing number of clinical trials of drug for the treatment of neuromyelitis optica spectrum disorder (NMOSD) by company is another factor that is expected to drive the global neuromyelitis optica therapy market growth. For instance, in September 2019, Chugai Pharmaceutical Co., Ltd.  announced positive results of its phase 3 clinical study of satralizumab drug, for the treatment of neuromyelitis optica spectrum disorder (NMOSD). From the same source, in 2019, Satralizumab had shown safety profile during the clinical trial and is first investigational drug that had demonstrated benefits both as a monotherapy and add-on therapy to baseline treatment in two different clinical trials. Furthermore, from the same source, in 2019, Chugai Pharmaceutical Co., Ltd also announced that they are going to collaborate with F. Hoffmann-La Roche AG Company. The main objective of this collaboration with Hoffmann-La Roche AG company is to file global regulatory application and bring Satralizumab as a potential new treatment to patients as soon as possible.

Furthermore, in October 2019, European Medicines Agency (EMA) and U.S. FDA accepted the marketing authorization of Satralizumab drug for the treatment of neuromyelitis optica spectrum disorder in adults and adolescent patients, which was announced by Chugai Pharmaceutical Co., Ltd.